Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Complement System
    (4)
TargetMol | Tags By Application
  • ELISA
    (1)
  • FCM
    (1)
  • Functional assay
    (1)
Filter
Search Result
Results for "

hemoglobinuria

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    3
    TargetMol | All_Pathways
  • Inhibitory Antibodies
    2
    TargetMol | Inhibitory_Antibodies
Iptacopan hydrochloride
LNP023 hydrochloride, Iptacopan HCl
T91891646321-63-2In house
Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. Iptacopan hydrochloride shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM.
  • $52
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Ravulizumab
ALXN1210
T768671803171-55-2
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity, targeting complement factor 5 to block complement activation. It can be used for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
  • $247
In Stock
Size
QTY
Danicopan
ACH-4471
T85091903768-17-1
Danicopan (ACH-4471) (ACH-4471) is a selective, orally active small molecule factor D inhibitor with high binding affinity to human factor D, with a Kd value of 0.54 nM. Danicopan (ACH-4471) inhibits the activity of the complement replacement pathway (APC) and may block the complement replacement pathway in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
  • $97
In Stock
Size
QTY